Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Biochem Pharmacol. 2018 Aug 4;156:32–42. doi: 10.1016/j.bcp.2018.08.003

Fig. 2. Testosterone glucuronide formation kinetics and inhibition in HLMs.

Fig. 2

A. Michaelis-Menten plot of testosterone glucuronide (TG) formation in high (orange), mid (black), and null (blue) UGT2B17-expressing HLMs; B&C. Inhibition of imatinib in high (orange) and low (blue) UGT2B17-expressing HLMs with testosterone (B) and oxazepam (C) as probe substrates for UGT2B17 and UGT2B15, respectively; D. Percent TG formation in high UGT2B17-expressing HLM inhibited by various tyrosine kinase inhibitors at 1 μM and 25 μM.